Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DXRP68
|
|||
| Drug Name |
Vutrisiran
|
|||
| Synonyms |
ALN-TTRsc02
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Hereditary amyloidosis [ICD-11: 5D00.2; ICD-10: E85.2] | Approved | [1] | |
| Transthyretin familial amyloid cardiomyopathy [ICD-11: 5D00.20; ICD-10: E85.1] | Phase 3 | [2] | ||
| Company |
Alnylam Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Transthyretin messenger RNA (TTR mRNA) | Target Info | Inhibitor | [3] |
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | |||
| Reactome | Retinoid cycle disease events | |||
| The canonical retinoid cycle in rods (twilight vision) | ||||
| Non-integrin membrane-ECM interactions | ||||
| Retinoid metabolism and transport | ||||
| Amyloid formation | ||||
| WikiPathways | Visual phototransduction | |||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215515. | |||
| REF 2 | ClinicalTrials.gov (NCT03759379) HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.